Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (ABBV -1.23%) is no exception. Nonetheless, the next five years will likely see it growing faster than the last five years, and shareholders are apt to benefit.Here's where this company will be going, and where it's probably going to end up.It's hard to see this business getting any smallerIn the next five years, expect AbbVie to continue to compete in the disease areas t ...

AbbVie (ABBV) announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab soravtansine) for treating platinum-resistant ovarian cancer.The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatments.Following the approval, Elahere became the first and only FRα-directe ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Analyst’s Disclosure: I/we have a beneficial long position in the shares of PEP, LMT, NOC, ABBV, UNP, ODFL, LHX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (o ...

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the companion diagnostic to identify ovarian cancer patients eligible for ELAHERE, also receives CE MarkNORTH CHICAGO, Ill., Nov. ...

AbbVie’s (ABBV) stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily oral candidate for treating schizophrenia, failed to meet their primary endpoints. Emraclidine was added to AbbVie’s pipeline with this year’s acquisition of Cerevel and was a key reason for AbbVie to buy the company, thus bringing into question the viability of the deal.The failure of the phase II s ...

The drugmaker has convincingly laid to rest the biggest threat to its top line.It's always a good sign when a company successfully navigates a period of uncertainty with the help of a well-executed plan. For AbbVie, (ABBV -0.42%) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years.Here's how this drugmaker proved the bears wrong, and why that means it's worth investing $1,500 in today.A major period of uncertainty is endingAt the start o ...

These companies have solid businesses and excellent dividend growth track records.The healthcare sector might not be at the forefront of exciting developments like artificial intelligence, but because good medical care is always in high demand, many healthcare companies boast stable, reliable businesses. That's precisely the kind that can also sustain growing dividends, making the industry pretty attractive for income-oriented investors.Which healthcare stock can dividend investors safely buy? Let's conside ...

AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace Nearly 40 million Americans are living with migraine, a debilitating neurological disease, and are more likely to call in sick due to symptoms associated with migraine.1-2NORTH CHICAGO, Ill., Nov. 14, 2024 /PRNewswire/ -- AbbVie ...

I'm an investment analyst with clinical experience in healthcare and an MBA, expanding my focus from biotech to a range of sectors. I've had the privilege of sharing my insights on Seeking Alpha since 2017, emphasizing financial modeling techniques like DCF analysis to identify underlying assumptions in stock valuations. I provide scenario-based forecasts to help readers gauge reasonable outcomes. Influenced by works like Superforecasting and Antifragile, I advocate for disciplined risk management through a ...

On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.Truist says due to the failure, Bristol Myers Squibb & Co’s BMY Cobenfy (xanomeline and trospium ...